Table 3.
Efficacy outcomes at baseline and following supplementation with collagen peptides, whey protein or placebo.
| CP-G (n = 30) | P-G (n = 31) | WP-G (n = 36) | p Value LMM | ||||
|---|---|---|---|---|---|---|---|
| T0 | T12 | T0 | T12 | T0 | T12 | ||
| Fat free mass (kg) | 60.4 ± 4.78 | 63.8 ± 6.03 *** | 58.5 ± 6.29 | 60.3 ± 5.71 *** | 59.6 ± 6.22 | 61.9 ± 6.76 *** | 0.033 |
| Fat free mass (%) | 60.8 ± 4.50 | 65.3 ± 4.76 *** | 61.4 ± 4.31 | 64.4 ± 5.02 *** | 60.8 ± 3.29 | 64.3 ± 4.67 *** | 0.066 |
| Skeletal muscle mass 1 | 30.8 ± 2.42 | 32.1 ± 3.02 *** | 30.0 ± 3.18 | 30.5 ± 2.85 * | 30.5 ± 3.13 | 31.2 ± 3.33 ** | 0.037 |
| Fat mass (kg) | 35.9 ± 7.11 | 30.6 ± 6.48 *** | 33.7 ± 6.89 | 30.3 ± 7.57 *** | 35.4 ± 6.44 | 31.3 ± 7.40 *** | 0.054 |
| Fat mass (%) | 35.8 ± 4.71 | 31.1 ± 5.06 *** | 35.1 ± 4.53 | 31.9 ± 5.30 *** | 35.8 ± 3.45 | 32.1 ± 4.94 *** | 0.083 |
| Bone mineral content (kg) | 3.34 ± 0.339 | 3.57 ± 0.460 ** | 3.34 ± 0.380 | 3.49 ± 0.442 * | 3.25 ± 0.350 | 3.40 ± 0.311 ** | 0.325 |
| Bone mineral content (%) | 3.37 ± 0.376 | 3.66 ± 0.439 *** | 3.52 ± 0.371 | 3.76 ± 0.533 ** | 3.37 ± 0.393 | 3.58 ± 0.423 *** | 0.642 |
| Body weight (kg) | 99.6 ± 9.00 | 98.0 ± 8.49 *** | 95.5 ± 10.8 | 94.1 ± 10.8 * | 98.3 ± 11.5 | 96.6 ± 11.5 *** | 0.899 |
| Waist circumference (cm) | 107.5 ± 6.67 † | 104.1 ± 6.49 *** | 102.9 ± 7.00 † | 100.4 ± 7.77 ** | 105.6 ± 7.11 | 103.2 ± 7.86 *** | 0.561 |
| Muscle strength (N) | 1695 ± 378.7 | 1858 ± 399.2 *** | 1706 ± 351.8 | 1806 ± 365.9 ** | 1633 ± 370.5 | 1753 ± 355.7 ** | 0.444 |
Data represent mean ± SD; p value LMM, significance between groups in linear mixed model testing assessing treatment × time interaction; † = p < 0.05 between groups at baseline; * = p < 0.05; ** = p < 0.01; *** = p < 0.001 within the group from baseline to final examination. 1 Estimated skeletal muscle mass according to Kim et al. [33]. Bold numbers represent statistical significance of the primary endpoint.